| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community Pharmacy Services | 1 | 2016 | 6 | 0.520 |
Why?
|
| Community Health Planning | 1 | 2016 | 22 | 0.510 |
Why?
|
| Professional Role | 1 | 2016 | 42 | 0.500 |
Why?
|
| Precision Medicine | 3 | 2021 | 451 | 0.480 |
Why?
|
| Genetic Heterogeneity | 1 | 2014 | 70 | 0.420 |
Why?
|
| Patient Care Team | 1 | 2016 | 307 | 0.420 |
Why?
|
| Colorectal Neoplasms | 3 | 2012 | 1069 | 0.420 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 456 | 0.390 |
Why?
|
| DNA Glycosylases | 1 | 2012 | 25 | 0.380 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2012 | 42 | 0.370 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2012 | 45 | 0.370 |
Why?
|
| Haplotypes | 1 | 2014 | 650 | 0.370 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2012 | 395 | 0.360 |
Why?
|
| Antineoplastic Agents | 11 | 2021 | 2422 | 0.350 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 2860 | 0.340 |
Why?
|
| Neoplasms | 9 | 2023 | 3250 | 0.330 |
Why?
|
| Adenoma | 1 | 2012 | 260 | 0.320 |
Why?
|
| Skin Neoplasms | 7 | 2013 | 625 | 0.300 |
Why?
|
| Breast Neoplasms | 19 | 2013 | 3147 | 0.270 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1665 | 0.240 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2006 | 156 | 0.230 |
Why?
|
| Humans | 75 | 2023 | 96127 | 0.210 |
Why?
|
| Mutation | 3 | 2023 | 4374 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 407 | 0.190 |
Why?
|
| Aged | 41 | 2021 | 20964 | 0.190 |
Why?
|
| Middle Aged | 47 | 2021 | 28363 | 0.180 |
Why?
|
| Prostatic Neoplasms | 6 | 2016 | 1798 | 0.180 |
Why?
|
| Female | 53 | 2021 | 50063 | 0.180 |
Why?
|
| Dietary Fats | 4 | 2009 | 137 | 0.180 |
Why?
|
| Postmenopause | 7 | 2013 | 107 | 0.180 |
Why?
|
| ErbB Receptors | 1 | 2005 | 513 | 0.180 |
Why?
|
| Sickle Cell Trait | 1 | 2021 | 21 | 0.170 |
Why?
|
| Outpatients | 1 | 2021 | 105 | 0.170 |
Why?
|
| Viral Load | 1 | 2021 | 164 | 0.170 |
Why?
|
| Venous Thromboembolism | 1 | 2023 | 171 | 0.170 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 72 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 611 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2021 | 898 | 0.160 |
Why?
|
| Thrombosis | 1 | 2023 | 326 | 0.160 |
Why?
|
| Genital Neoplasms, Female | 1 | 2021 | 115 | 0.160 |
Why?
|
| Patient Care Planning | 2 | 2021 | 89 | 0.150 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 348 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 2 | 2005 | 1431 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2015 | 1469 | 0.140 |
Why?
|
| Carcinoma, Basal Cell | 3 | 2004 | 63 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 539 | 0.140 |
Why?
|
| Isotretinoin | 1 | 2017 | 20 | 0.130 |
Why?
|
| Male | 34 | 2021 | 45870 | 0.130 |
Why?
|
| Ovarian Neoplasms | 5 | 2007 | 828 | 0.130 |
Why?
|
| Coronary Artery Disease | 2 | 2012 | 394 | 0.130 |
Why?
|
| Patient Education as Topic | 2 | 2015 | 378 | 0.130 |
Why?
|
| Genetic Testing | 2 | 2021 | 565 | 0.130 |
Why?
|
| Molecular Biology | 1 | 1997 | 90 | 0.130 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 901 | 0.130 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 64 | 0.130 |
Why?
|
| Dermatologic Agents | 1 | 2017 | 77 | 0.120 |
Why?
|
| Carcinoma | 3 | 1995 | 449 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 1997 | 229 | 0.120 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 174 | 0.120 |
Why?
|
| Aftercare | 1 | 1996 | 90 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 1105 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2016 | 215 | 0.110 |
Why?
|
| Cisplatin | 2 | 1990 | 611 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 247 | 0.110 |
Why?
|
| Pleural Effusion, Malignant | 1 | 1995 | 16 | 0.110 |
Why?
|
| Pleura | 1 | 1995 | 32 | 0.110 |
Why?
|
| Melanoma | 2 | 2012 | 497 | 0.110 |
Why?
|
| Prospective Studies | 10 | 2023 | 4671 | 0.110 |
Why?
|
| Self Care | 1 | 2015 | 170 | 0.110 |
Why?
|
| Health Promotion | 1 | 2015 | 176 | 0.100 |
Why?
|
| Dysgerminoma | 1 | 1993 | 7 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 381 | 0.100 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 1993 | 39 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 2 | 2012 | 155 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 228 | 0.100 |
Why?
|
| Malpractice | 1 | 1993 | 57 | 0.100 |
Why?
|
| Risk | 3 | 2011 | 668 | 0.090 |
Why?
|
| Risk Factors | 7 | 2023 | 5960 | 0.090 |
Why?
|
| Adenocarcinoma | 9 | 1994 | 1215 | 0.090 |
Why?
|
| Breast | 3 | 2010 | 297 | 0.090 |
Why?
|
| Anthropometry | 1 | 2011 | 78 | 0.090 |
Why?
|
| Mass Screening | 1 | 1996 | 710 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 2 | 2017 | 1089 | 0.090 |
Why?
|
| Demography | 1 | 2011 | 189 | 0.090 |
Why?
|
| Lip Neoplasms | 1 | 1990 | 7 | 0.090 |
Why?
|
| Total Quality Management | 1 | 2011 | 34 | 0.090 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2012 | 162 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 363 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 1993 | 382 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2004 | 107 | 0.080 |
Why?
|
| Adult | 25 | 2021 | 28718 | 0.080 |
Why?
|
| Time Factors | 6 | 2013 | 5585 | 0.080 |
Why?
|
| Electronic Health Records | 2 | 2012 | 372 | 0.080 |
Why?
|
| Amygdalin | 2 | 1980 | 3 | 0.080 |
Why?
|
| Linoleic Acid | 1 | 2009 | 5 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2007 | 2040 | 0.080 |
Why?
|
| Arachidonic Acid | 1 | 2009 | 65 | 0.080 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2009 | 22 | 0.080 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2011 | 123 | 0.080 |
Why?
|
| Coronary Artery Bypass | 1 | 2012 | 252 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 437 | 0.080 |
Why?
|
| Docosahexaenoic Acids | 1 | 2009 | 35 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 107 | 0.080 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 71 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2007 | 2642 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2012 | 647 | 0.070 |
Why?
|
| United States | 5 | 2017 | 7767 | 0.070 |
Why?
|
| Quality Improvement | 1 | 2012 | 502 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 2 | 2007 | 725 | 0.070 |
Why?
|
| CA-125 Antigen | 1 | 2007 | 22 | 0.070 |
Why?
|
| Drug Evaluation | 13 | 1989 | 136 | 0.070 |
Why?
|
| alpha-Fetoproteins | 1 | 2007 | 46 | 0.070 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 2001 | 96 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2010 | 1268 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2010 | 447 | 0.060 |
Why?
|
| Odds Ratio | 3 | 2021 | 713 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2010 | 684 | 0.060 |
Why?
|
| Teniposide | 2 | 1986 | 6 | 0.060 |
Why?
|
| Podophyllotoxin | 2 | 1986 | 10 | 0.060 |
Why?
|
| Internal Medicine | 2 | 2011 | 371 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 554 | 0.060 |
Why?
|
| Urologic Neoplasms | 2 | 1989 | 78 | 0.060 |
Why?
|
| Women's Health | 3 | 2013 | 109 | 0.060 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 3927 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2494 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2001 | 114 | 0.060 |
Why?
|
| Work Schedule Tolerance | 1 | 2005 | 37 | 0.060 |
Why?
|
| Neoplasm Metastasis | 10 | 2007 | 1103 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 750 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 1192 | 0.060 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 1989 | 156 | 0.060 |
Why?
|
| Neoplasm Staging | 7 | 2017 | 2081 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 346 | 0.060 |
Why?
|
| Biomarkers | 1 | 2012 | 1933 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2010 | 1730 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2007 | 338 | 0.060 |
Why?
|
| Endometrial Neoplasms | 1 | 2007 | 228 | 0.050 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2005 | 102 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 3 | 2009 | 590 | 0.050 |
Why?
|
| Liver Neoplasms | 3 | 2007 | 793 | 0.050 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 7232 | 0.050 |
Why?
|
| Progesterone Congeners | 1 | 2003 | 4 | 0.050 |
Why?
|
| Factor V | 1 | 2023 | 9 | 0.050 |
Why?
|
| Prothrombin | 1 | 2023 | 19 | 0.050 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2003 | 16 | 0.050 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2003 | 23 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2007 | 426 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2003 | 48 | 0.050 |
Why?
|
| Diethylstilbestrol | 2 | 1985 | 119 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 1807 | 0.050 |
Why?
|
| Reminder Systems | 2 | 2012 | 18 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2012 | 9173 | 0.040 |
Why?
|
| Preexisting Condition Coverage | 1 | 2021 | 3 | 0.040 |
Why?
|
| Hemangiosarcoma | 1 | 2001 | 17 | 0.040 |
Why?
|
| Hypoglycemia | 1 | 1982 | 112 | 0.040 |
Why?
|
| Menogaril | 1 | 2001 | 3 | 0.040 |
Why?
|
| Population | 1 | 2021 | 37 | 0.040 |
Why?
|
| Vascular Neoplasms | 1 | 2001 | 21 | 0.040 |
Why?
|
| Thiadiazoles | 2 | 1994 | 12 | 0.040 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2001 | 37 | 0.040 |
Why?
|
| Prognosis | 5 | 2017 | 4033 | 0.040 |
Why?
|
| Neutropenia | 1 | 2021 | 218 | 0.040 |
Why?
|
| United Kingdom | 1 | 2021 | 192 | 0.040 |
Why?
|
| Rectal Neoplasms | 3 | 1987 | 134 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 191 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2016 | 1546 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2021 | 175 | 0.040 |
Why?
|
| Polycomb Repressive Complex 2 | 2 | 2010 | 32 | 0.040 |
Why?
|
| Adenoma, Islet Cell | 1 | 1979 | 28 | 0.040 |
Why?
|
| Mammography | 1 | 2003 | 475 | 0.040 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2010 | 41 | 0.040 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1979 | 16 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 547 | 0.040 |
Why?
|
| Semustine | 1 | 1979 | 2 | 0.040 |
Why?
|
| Nitrosourea Compounds | 1 | 1979 | 9 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 1979 | 51 | 0.040 |
Why?
|
| Glucagon | 1 | 1979 | 115 | 0.040 |
Why?
|
| Glioblastoma | 2 | 1996 | 286 | 0.040 |
Why?
|
| Neoplasm Seeding | 1 | 1979 | 16 | 0.040 |
Why?
|
| Incidence | 3 | 2012 | 1715 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 1996 | 501 | 0.040 |
Why?
|
| Nipples | 1 | 1979 | 38 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 305 | 0.040 |
Why?
|
| Methylation | 2 | 2010 | 295 | 0.040 |
Why?
|
| Combined Modality Therapy | 6 | 1996 | 1773 | 0.040 |
Why?
|
| Heat-Shock Proteins | 1 | 1999 | 184 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2010 | 527 | 0.040 |
Why?
|
| Histones | 2 | 2010 | 364 | 0.030 |
Why?
|
| Physical Examination | 3 | 1996 | 154 | 0.030 |
Why?
|
| Animals | 4 | 2014 | 28945 | 0.030 |
Why?
|
| Carcinoma 256, Walker | 2 | 1979 | 4 | 0.030 |
Why?
|
| Colonic Neoplasms | 3 | 1987 | 589 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1978 | 126 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1998 | 276 | 0.030 |
Why?
|
| Time | 1 | 1977 | 79 | 0.030 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1977 | 30 | 0.030 |
Why?
|
| Paclitaxel | 1 | 1998 | 498 | 0.030 |
Why?
|
| Mesothelioma | 2 | 1995 | 333 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2021 | 10286 | 0.030 |
Why?
|
| Benzoquinones | 2 | 1987 | 27 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 2 | 1987 | 45 | 0.030 |
Why?
|
| Brain Neoplasms | 3 | 1996 | 855 | 0.030 |
Why?
|
| Medical History Taking | 1 | 1996 | 88 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2005 | 1134 | 0.030 |
Why?
|
| Transitional Care | 1 | 2015 | 20 | 0.030 |
Why?
|
| Gene Expression | 1 | 1999 | 1322 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 404 | 0.030 |
Why?
|
| Thoracotomy | 1 | 1995 | 68 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 1998 | 354 | 0.030 |
Why?
|
| Health Care Costs | 1 | 1996 | 255 | 0.030 |
Why?
|
| Survival Rate | 2 | 1996 | 1986 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 204 | 0.030 |
Why?
|
| Drainage | 1 | 1995 | 172 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2015 | 198 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2010 | 2794 | 0.030 |
Why?
|
| Uterine Neoplasms | 1 | 1978 | 278 | 0.030 |
Why?
|
| New Jersey | 1 | 1993 | 5 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 180 | 0.030 |
Why?
|
| Sunlight | 1 | 2013 | 28 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2007 | 1973 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1791 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 908 | 0.020 |
Why?
|
| Radioisotope Teletherapy | 1 | 1992 | 4 | 0.020 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1992 | 6 | 0.020 |
Why?
|
| Cobalt Radioisotopes | 1 | 1992 | 19 | 0.020 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2012 | 43 | 0.020 |
Why?
|
| Reimbursement, Incentive | 1 | 2012 | 39 | 0.020 |
Why?
|
| Zoxazolamine | 1 | 1972 | 2 | 0.020 |
Why?
|
| Hexobarbital | 1 | 1972 | 2 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2012 | 2480 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 98 | 0.020 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2012 | 7 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1958 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 1972 | 49 | 0.020 |
Why?
|
| Patient Compliance | 1 | 1993 | 239 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1963 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2012 | 110 | 0.020 |
Why?
|
| Feedback | 1 | 2012 | 139 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2012 | 53 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2012 | 58 | 0.020 |
Why?
|
| Phosphoric Acids | 1 | 1971 | 5 | 0.020 |
Why?
|
| Troponin I | 1 | 2012 | 27 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 1993 | 514 | 0.020 |
Why?
|
| Myocardium | 2 | 2012 | 596 | 0.020 |
Why?
|
| Recurrence | 1 | 1995 | 1218 | 0.020 |
Why?
|
| Insecticides | 1 | 1971 | 27 | 0.020 |
Why?
|
| Complement Activation | 1 | 2012 | 84 | 0.020 |
Why?
|
| Cyclophosphamide | 4 | 1992 | 313 | 0.020 |
Why?
|
| Vitamin D | 1 | 2013 | 273 | 0.020 |
Why?
|
| Drug Therapy, Combination | 3 | 1983 | 813 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 380 | 0.020 |
Why?
|
| Drug Administration Schedule | 3 | 1998 | 873 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 186 | 0.020 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2010 | 6 | 0.020 |
Why?
|
| Polycomb-Group Proteins | 1 | 2010 | 10 | 0.020 |
Why?
|
| Documentation | 1 | 2011 | 103 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 1972 | 264 | 0.020 |
Why?
|
| Mitoguazone | 1 | 1989 | 2 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2010 | 81 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2009 | 21 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 23 | 0.020 |
Why?
|
| Vinblastine | 1 | 1989 | 100 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2011 | 155 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 438 | 0.020 |
Why?
|
| Oxazoles | 1 | 1989 | 18 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2010 | 106 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2011 | 151 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2011 | 263 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 112 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2010 | 152 | 0.020 |
Why?
|
| Aziridines | 2 | 1987 | 9 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 323 | 0.020 |
Why?
|
| Isoxazoles | 1 | 1989 | 78 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1993 | 1619 | 0.020 |
Why?
|
| Clinical Trials as Topic | 6 | 1987 | 1178 | 0.020 |
Why?
|
| Leukopenia | 3 | 1985 | 68 | 0.020 |
Why?
|
| Lysine | 1 | 2010 | 190 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 429 | 0.020 |
Why?
|
| Thyroid Neoplasms | 2 | 1986 | 443 | 0.020 |
Why?
|
| Cadherins | 1 | 2009 | 180 | 0.020 |
Why?
|
| Kidney Neoplasms | 2 | 1985 | 558 | 0.020 |
Why?
|
| Length of Stay | 1 | 2012 | 833 | 0.020 |
Why?
|
| Edible Grain | 1 | 2007 | 9 | 0.020 |
Why?
|
| Fluorouracil | 3 | 1992 | 555 | 0.020 |
Why?
|
| Vegetables | 1 | 2007 | 50 | 0.020 |
Why?
|
| Fruit | 1 | 2007 | 81 | 0.020 |
Why?
|
| Acid Phosphatase | 2 | 1985 | 34 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1175 | 0.020 |
Why?
|
| Liver | 1 | 1972 | 1238 | 0.020 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2007 | 69 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 416 | 0.020 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2007 | 59 | 0.020 |
Why?
|
| Astrocytoma | 1 | 1987 | 89 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2007 | 215 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 3107 | 0.020 |
Why?
|
| Chicago | 1 | 2011 | 1503 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2010 | 710 | 0.020 |
Why?
|
| Quinazolines | 1 | 2007 | 216 | 0.020 |
Why?
|
| Lung Neoplasms | 4 | 1995 | 2463 | 0.010 |
Why?
|
| Medulloblastoma | 1 | 1986 | 44 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2007 | 244 | 0.010 |
Why?
|
| Azirines | 1 | 1985 | 3 | 0.010 |
Why?
|
| Weight Loss | 1 | 2007 | 240 | 0.010 |
Why?
|
| Radio Waves | 1 | 1985 | 20 | 0.010 |
Why?
|
| Job Satisfaction | 1 | 2005 | 86 | 0.010 |
Why?
|
| Germanium | 1 | 1984 | 4 | 0.010 |
Why?
|
| Anthraquinones | 1 | 1984 | 8 | 0.010 |
Why?
|
| Mitolactol | 1 | 1984 | 1 | 0.010 |
Why?
|
| Spiro Compounds | 1 | 1984 | 30 | 0.010 |
Why?
|
| Medical Errors | 1 | 2005 | 119 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 185 | 0.010 |
Why?
|
| Workload | 1 | 2005 | 133 | 0.010 |
Why?
|
| Sleep Deprivation | 1 | 2005 | 133 | 0.010 |
Why?
|
| Hyperthermia, Induced | 1 | 1985 | 75 | 0.010 |
Why?
|
| BCG Vaccine | 2 | 1984 | 38 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 1351 | 0.010 |
Why?
|
| Burnout, Professional | 1 | 2005 | 113 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 771 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 1763 | 0.010 |
Why?
|
| Organometallic Compounds | 1 | 1984 | 148 | 0.010 |
Why?
|
| Interferon Type I | 1 | 1985 | 206 | 0.010 |
Why?
|
| Thyroxine | 1 | 1986 | 388 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 1984 | 174 | 0.010 |
Why?
|
| Mastectomy | 3 | 1980 | 270 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1983 | 271 | 0.010 |
Why?
|
| Indomethacin | 1 | 1983 | 62 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 7025 | 0.010 |
Why?
|
| Glioma | 1 | 1985 | 321 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 599 | 0.010 |
Why?
|
| Radiotherapy | 2 | 1986 | 328 | 0.010 |
Why?
|
| Interferons | 1 | 1983 | 130 | 0.010 |
Why?
|
| Carmustine | 2 | 1996 | 71 | 0.010 |
Why?
|
| Attitude | 1 | 1983 | 137 | 0.010 |
Why?
|
| Pheochromocytoma | 1 | 1982 | 52 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1982 | 90 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 1982 | 235 | 0.010 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1982 | 85 | 0.010 |
Why?
|
| Energy Intake | 2 | 1993 | 100 | 0.010 |
Why?
|
| Monocytes | 1 | 1983 | 231 | 0.010 |
Why?
|
| Syndrome | 1 | 1982 | 453 | 0.010 |
Why?
|
| Depression | 1 | 2005 | 560 | 0.010 |
Why?
|
| Random Allocation | 3 | 1986 | 327 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2001 | 108 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2012 | 2591 | 0.010 |
Why?
|
| Heart Failure | 1 | 2011 | 1422 | 0.010 |
Why?
|
| Pleural Neoplasms | 1 | 1982 | 205 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1980 | 111 | 0.010 |
Why?
|
| Rodentia | 1 | 1980 | 47 | 0.010 |
Why?
|
| Lymphedema | 1 | 2001 | 84 | 0.010 |
Why?
|
| Streptozocin | 1 | 1979 | 56 | 0.010 |
Why?
|
| Rats | 2 | 1979 | 4154 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1979 | 54 | 0.010 |
Why?
|
| Cyanides | 1 | 1979 | 16 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1979 | 64 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1979 | 88 | 0.010 |
Why?
|
| Infusions, Intravenous | 2 | 1989 | 423 | 0.010 |
Why?
|
| DNA Primers | 1 | 1999 | 548 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1979 | 115 | 0.010 |
Why?
|
| Physicians | 1 | 2005 | 707 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1998 | 169 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2004 | 1874 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1979 | 362 | 0.010 |
Why?
|
| Doxorubicin | 2 | 1992 | 304 | 0.010 |
Why?
|
| Skin | 1 | 2001 | 605 | 0.010 |
Why?
|
| Adolescent | 4 | 1987 | 9896 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1979 | 458 | 0.010 |
Why?
|
| Chlorambucil | 1 | 1977 | 23 | 0.010 |
Why?
|
| Quality of Life | 1 | 2005 | 1816 | 0.010 |
Why?
|
| Bone Neoplasms | 3 | 1985 | 320 | 0.010 |
Why?
|
| Long-Term Care | 1 | 1977 | 63 | 0.010 |
Why?
|
| Mitomycin | 1 | 1996 | 29 | 0.010 |
Why?
|
| Karnofsky Performance Status | 1 | 1996 | 44 | 0.010 |
Why?
|
| Mercaptopurine | 1 | 1996 | 53 | 0.010 |
Why?
|
| Cell Line | 1 | 1999 | 2533 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 1996 | 231 | 0.010 |
Why?
|
| Vitamins | 1 | 1993 | 86 | 0.010 |
Why?
|
| Receptors, Estrogen | 2 | 1984 | 417 | 0.010 |
Why?
|
| Melphalan | 2 | 1984 | 100 | 0.010 |
Why?
|
| Benz(a)Anthracenes | 1 | 1972 | 4 | 0.010 |
Why?
|
| Body Weight | 1 | 1993 | 460 | 0.010 |
Why?
|
| Sarcoma, Experimental | 1 | 1972 | 53 | 0.010 |
Why?
|
| Paralysis | 1 | 1972 | 34 | 0.010 |
Why?
|
| Organophosphate Poisoning | 1 | 1971 | 2 | 0.010 |
Why?
|
| Poisoning | 1 | 1971 | 42 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1972 | 510 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1972 | 413 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1993 | 819 | 0.010 |
Why?
|
| Organ Size | 1 | 1972 | 379 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1990 | 183 | 0.000 |
Why?
|
| Postoperative Care | 2 | 1980 | 239 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1971 | 522 | 0.000 |
Why?
|
| Dacarbazine | 1 | 1987 | 101 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1987 | 236 | 0.000 |
Why?
|
| Vincristine | 1 | 1986 | 113 | 0.000 |
Why?
|
| Cyclohexenes | 1 | 1985 | 5 | 0.000 |
Why?
|
| Gastrointestinal Diseases | 1 | 1987 | 154 | 0.000 |
Why?
|
| Castration | 1 | 1985 | 37 | 0.000 |
Why?
|
| Thermal Conductivity | 1 | 1985 | 3 | 0.000 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1989 | 935 | 0.000 |
Why?
|
| Multi-Institutional Systems | 1 | 1985 | 4 | 0.000 |
Why?
|
| Stomach Ulcer | 1 | 1985 | 23 | 0.000 |
Why?
|
| Body Temperature | 1 | 1985 | 131 | 0.000 |
Why?
|
| Child | 2 | 1987 | 7626 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1985 | 228 | 0.000 |
Why?
|
| Mitoxantrone | 1 | 1984 | 68 | 0.000 |
Why?
|
| Prednisolone | 1 | 1984 | 37 | 0.000 |
Why?
|
| Anemia | 1 | 1985 | 137 | 0.000 |
Why?
|
| Nausea | 1 | 1985 | 182 | 0.000 |
Why?
|
| Vomiting | 1 | 1985 | 201 | 0.000 |
Why?
|
| Radiography | 1 | 1985 | 826 | 0.000 |
Why?
|
| Pulmonary Fibrosis | 1 | 1985 | 152 | 0.000 |
Why?
|
| Burns | 1 | 1985 | 150 | 0.000 |
Why?
|
| Phytohemagglutinins | 1 | 1983 | 21 | 0.000 |
Why?
|
| Pain Management | 1 | 1985 | 179 | 0.000 |
Why?
|
| Pain | 1 | 1985 | 426 | 0.000 |
Why?
|
| Cell Adhesion | 1 | 1983 | 444 | 0.000 |
Why?
|
| Cell Division | 1 | 1983 | 705 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1983 | 489 | 0.000 |
Why?
|
| Maxillary Neoplasms | 1 | 1980 | 7 | 0.000 |
Why?
|
| Hematuria | 1 | 1980 | 50 | 0.000 |
Why?
|
| Thymus Gland | 1 | 1979 | 206 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1986 | 3974 | 0.000 |
Why?
|
| Preoperative Care | 1 | 1980 | 418 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1983 | 763 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1986 | 2781 | 0.000 |
Why?
|